Table 1 Characteristics of studies included
Author | Year | Country | MA (Year) | Stage | NP | MF (month) | Cut-off | Dilution | Location | Positive rate | Survival endpoints | HR(e) | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liu [10] | 2013 | China | 52 | I–IV | 441 | NR | Scores > 4 | NR | NR | 39.50% | OS, PFS | Reported | 8 |
Wan [14] | 2017 | China | NR | NR | 314 | 240 | Scores ≥ 4 | NR | nuclear | 75.90% | OS, PFS | Reported | 9 |
Wu [22] | 2019 | China | 55.3 | I–III | 137 | NR | Scores ≥ 3 | 1:50 | nuclear | 24.10% | OS, PFS | Curve | 8 |
Gu [23] | 2019 | China | NR | I–IV | 108 | 88.5 | Scores ≥ 4 | 1:600 | cytoplasm | 46.30% | OS, PFS | Curve | 9 |
Prasad [24] | 2009 | India | 56 | NR | 98 | NR | > 10% | 1:50 | nuclear | 34% | NR | NR | 7 |
Cao [25] | 2015 | China | NR | I–IV | 200 | NR | > 10% | 1:50 | nuclear | 42% | NR | NR | 7 |
Ito [27] | 2015 | Japan | 54 | IV | 47 | 61 | > 5% | 1:500 | nuclear | 40% | PFS | Reported | 9 |
Wu [26] | 2012 | USA | NR | I–III | 113 | NR | NR | 1:100 | nuclear | 44% | OS | Reported | 6 |